Poly(acrylic acid) microspheres loaded with superparamagnetic iron oxide nanoparticles for transcatheter arterial embolization and MRI detectability: In vitro and in vivo evaluation

[Display omitted] To develop embolic microspheres with MRI detectability, superparamagnetic iron oxide nanoparticles (SPIONs) were synthesized and mixed with monomer of acrylic acid to prepare SPIONs-loaded polymerized microspheres (SPMs) by inverse suspension polymerization method. The SPMs were ev...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutics Vol. 527; no. 1-2; pp. 31 - 41
Main Authors Li, Zi-Yuan, Qin, Xiao-Ya, Guo, Li-Ying, Wang, Huan, Liu, Xiao-Xin, Zheng, Zhuo-Zhao, Guan, Hai-Tao, Song, Li, Zou, Ying-Hua, Fan, Tian-Yuan
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 15.07.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] To develop embolic microspheres with MRI detectability, superparamagnetic iron oxide nanoparticles (SPIONs) were synthesized and mixed with monomer of acrylic acid to prepare SPIONs-loaded polymerized microspheres (SPMs) by inverse suspension polymerization method. The SPMs were evaluated for the ability of embolization by investigating the morphology, particle size, elasticity and renal arterial embolization to rabbits. Meanwhile, the loading of SPIONs was verified by optical microscope, transmission electron microscope, Fourier transform infrared spectrum, vibrating sample magnetometer, X-ray diffraction and X-ray photoelectron spectroscopy, and the content of SPIONs in SPMs was measured quantitatively. Furthermore, the MRI detectability of SPMs was testified in gel phantom, mice and rabbits respectively by a clinical 3.0T MRI scanner. The results revealed the SPMs were potential MRI detectable embolic microspheres for improving the effectiveness and safety of embolotherapy in the future.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2017.04.069